Press Release | JW Therapeutics

Press Release

JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting

12 December, 2022

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients

09 November, 2022

JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies

27 October, 2022

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma

10 October, 2022

JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma

04 July, 2022

JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting

05 June, 2022

JW Therapeutics to Present Latest Data of Carteyva® at 2022 ASCO Annual Meeting

09 May, 2022

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 200 Chinese Patients

25 April, 2022

JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva® in Pediatric and Young Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

20 April, 2022

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China

03 April, 2022

JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma

31 March, 2022

JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma

27 February, 2022

JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building

10 January, 2022

JW Therapeutics Presents Primary Clinical Response on Carteyva® (relmacabtagene autoleucel injection) in Adults with Relapsed/Refractory Follicular Lymphoma in China at the 63rd ASH Annual Meeting

13 December, 2021

JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129

27 September, 2021

JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)

26 September, 2021

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China

06 September, 2021

JW Therapeutics Announces 2021 Interim Results

27 August, 2021

JW Therapeutics Announces Strategic Partnership with MediTrust Health

20 August, 2021

JW Therapeutics Announces 2020 Annual Results

26 March, 2021

JW Therapeutics and Thermo Fisher Scientific Announce CAR-T Partnership in China

03 February, 2021

JW Therapeutics Presents Data from Pivotal Trial of Relma-cel at the 62nd ASH Annual Meeting

07 December, 2020

Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX

03 November, 2020

JW Therapeutics and Lyell Immunopharma Announce Collaboration to Advance Solid Tumor Treatment in China

10 August, 2020

JW Acquires Syracuse Biopharma

20 July, 2020

JW Therapeutics Completes $ 100 Million Series B Financing

09 June, 2020

JW Therapeutics announced the grand opening of R&D center in Zhangjiang Science City of Pudong New Area, Shanghai

12 December, 2018

JW Therapeutics to Build Its First Commercial CAR-T Cell Manufacturing Plant in Suzhou, China

10 August, 2018

JW Therapeutics Closes $ 90 Million Series A Financing

08 March, 2018